Accordingly, the 1-, 3- and 5-year TTR rates of HCC patients with high level of LASS2 or TGF-β1 expression were significantly lower than those of HCC patients with low levels of LASS2 or TGF-β1 expression, respectively. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.